Register for the ESMO Post Show Roundtable
Highlights from the virtual conference
Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.
Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.
The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.